AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20185343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sodium hyaluronate (SH) injections (5 injections at weekly intervals)
Number of subjects: 40
Study 20185343 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution injections (5 injections at weekly intervals)
Number of subjects: 40
Study 20185343 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog pain score reduction
Number of subjects: 40
Study 18005508 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender‐ and culture‐specific behavioural interventions and interactive STI counselling
Number of subjects: 853
Study 18005508 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-abused women)
Number of subjects: 853
Study 18005508 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused adolescents (<19 years)
Number of subjects: 853
Study 18005508 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused adults
Number of subjects: 853
Study 15696451 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 12083600 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Management Techniques (BMTs)
Number of subjects: 0
Study 12083600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12083600 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 0
Study 12083600 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 10606280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, estramustine, or no therapy for 2 years (in NPCP 900/1000 trial)
Number of subjects: 0
Study 10606280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 0
Study 10606280 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine with vinblastine
Number of subjects: 0
Study 10606280 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 0
Study 8567833 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of basal body temperature graphs by experienced clinicians using uniform criteria
Number of subjects: 160
Study 1514337 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 50
Study 6337742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally every 6 hours for 12 weeks)
Number of subjects: 30
Study 6337742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally)
Number of subjects: 30
Study 6337742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6337742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (chronic therapy)
Number of subjects: 30
Study 30928678 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 73
Study 30928678 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 73
Study 30928678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 73
Study 30968632 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus Rhamnosus GG)
Number of subjects: 150
Study 30968632 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 150
Study 24444414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy (omeprazole 20 mg od)
Number of subjects: 117
Study 24444414 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (omeprazole 20 mg on-demand)
Number of subjects: 117
Study 24444414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy (omeprazole 20 mg od) in NERD
Number of subjects: 117
Study 24444414 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (omeprazole 20 mg on-demand) in NERD
Number of subjects: 117
Study 24444414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy (omeprazole 20 mg od) in RE
Number of subjects: 117
Study 24444414 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (omeprazole 20 mg on-demand) in RE
Number of subjects: 117
Study 22943930 — intervention group
Group type: EXPERIMENTAL
Intervention: DDB plus garlic oil (GO) - 2 capsules per day
Number of subjects: 88
Study 22943930 — intervention group
Group type: EXPERIMENTAL
Intervention: DDB plus garlic oil (GO) - 3 capsules per day
Number of subjects: 88
Study 22943930 — intervention group
Group type: EXPERIMENTAL
Intervention: DDB plus garlic oil (GO) - 6 capsules per day
Number of subjects: 88
Study 22943930 — intervention group
Group type: EXPERIMENTAL
Intervention: DDB plus garlic oil (GO) - all doses
Number of subjects: 88
Study 22943930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 19445819 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Na base-producing (LNAB) DASH-type diet including six serves lean red meat/week
Number of subjects: 95
Study 19445819 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-fat (HCLF) diet with a higher acid load
Number of subjects: 95
Study 19445819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study 17304454 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cultures
Number of subjects: 204
Study 17304454 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential quantitative blood cultures
Number of subjects: 204
Study 17304454 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential time to positivity
Number of subjects: 204
Study 15338257 — intervention group
Group type: COMPARATOR
Intervention: Anti-oxLDL levels in SLE patients with APS
Number of subjects: 70
Study 15338257 — intervention group
Group type: COMPARATOR
Intervention: Anti-oxLDL levels in SLE patients without APS
Number of subjects: 70
Study 15338257 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive oxygen species production in SLE patients without APS
Number of subjects: 70
Study 15338257 — intervention group
Group type: COMPARATOR
Intervention: oxLDL levels in APS patients
Number of subjects: 70
Study 15338257 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Anti-oxLDL levels with anticardiolipin antibodies
Number of subjects: 70
Study 15338257 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Anti-oxLDL levels with beta(2)-glycoprotein I antibodies
Number of subjects: 70
Study 11349744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime 3 g/day
Number of subjects: 35
Study 11349744 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ceftazidime 2 g 3 times/day
Number of subjects: 35
Study 11349744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime
Number of subjects: 35
Study 11349744 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ceftazidime
Number of subjects: 35
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with modified CODBLAM IV regimen
Number of subjects: 54
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐C at low doses plus alphaIFN
Number of subjects: 54
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU + vinblastine
Number of subjects: 54
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: alphaIFN as maintenance therapy
Number of subjects: 54
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and failure-free survival rates
Number of subjects: 54
Study 9625813 — intervention group
Group type: EXPERIMENTAL
Intervention: Median follow-up
Number of subjects: 54
Study 7943077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg, two doses 6 hours apart)
Number of subjects: 158
Study 7943077 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (12 hours, up to 4 mlU/min)
Number of subjects: 158
Study 3286393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine infusion
Number of subjects: 0
Study 3286393 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 0
Study 31978882 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of preoperative hydrocortisone (group HC, n = 20)
Number of subjects: 40
Study 31978882 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C, n = 20)
Number of subjects: 40
Study 31978882 — intervention group
Group type: COMPARATOR
Intervention: Postoperative 3-month pituitary hormone outcomes including ACTH deficiency
Number of subjects: 40
Study 30446594 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glyburide
Number of subjects: 77
Study 30446594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 26830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy alone (32%) or in combination with other agents (17%)
Number of subjects: 0
Study 26830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral agents
Number of subjects: 0
Study 26830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 26830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 26830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 24755214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored de-implementation strategy (interactive education, feedback in educational outreach visits, electronically sent reports on hospital performance, information letters/emails)
Number of subjects: 20
Study 24755214 — intervention group
Group type: COMPARATOR
Intervention: Control strategy (passive dissemination of available evidence)
Number of subjects: 20
Study 23307105 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoroquinolone use at presentation
Number of subjects: 480
Study 23307105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-generation fluoroquinolones
Number of subjects: 480
Study 20629549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved amniotic membrane (CAM)
Number of subjects: 0
Study 20629549 — intervention group
Group type: COMPARATOR
Intervention: Control (conventionally managed lesions)
Number of subjects: 0
Study 17551931 — intervention group
Group type: EXPERIMENTAL
Intervention: First-event-only method
Number of subjects: 400
Study 17551931 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal method
Number of subjects: 400
Study 16175188 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CA19-9 above median value
Number of subjects: 154
Study 16175188 — intervention group
Group type: COMPARATOR
Intervention: Baseline CA19-9 below median value
Number of subjects: 154
Study 16175188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall of 20% in CA19-9 level from baseline
Number of subjects: 154
Study 12514592 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm to 7-mm grafts
Number of subjects: 109
Study 12514592 — intervention group
Group type: COMPARATOR
Intervention: 6-mm grafts
Number of subjects: 109
Study 10821722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg oral solution once daily)
Number of subjects: 141
Study 10821722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg or 20 mg tablets once daily)
Number of subjects: 141
Study 10821722 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.075 mg/kg oral solution three times daily)
Number of subjects: 141
Study 10821722 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (2.5 mg tablets three times daily)
Number of subjects: 141
Study 10821722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Bambuterol and Terbutaline)
Number of subjects: 141
Study 8876850 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl salicylate (12.5%) applied as an ointment, 5 g twice daily for 4 days (8 doses)
Number of subjects: 12
Study 8876850 — intervention group
Group type: COMPARATOR
Intervention: Trolamine salicylate (10%) applied as a cream, 5 g twice daily for two doses
Number of subjects: 12
Study 1545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) to 10 fish species
Number of subjects: 11
Study 1545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges to fish species
Number of subjects: 11
Study 1545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analyses with sera from fish-allergic patients
Number of subjects: 11
Study 1545094 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA‐inhibition assays
Number of subjects: 11
Study 1545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of other fish species
Number of subjects: 11
Study 6694555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6694555 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 6694555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 0
Study 6694555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30717811 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT-aided SLNE
Number of subjects: 0
Study 30717811 — intervention group
Group type: COMPARATOR
Intervention: Standard SLNE
Number of subjects: 0
Study 30304428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion plus standard therapy (n=224 patients)
Number of subjects: 450
Study 30304428 — intervention group
Group type: COMPARATOR
Intervention: Sham hemoperfusion plus standard therapy (n=226 patients)
Number of subjects: 450
Study 30304428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion plus standard therapy (n=146 patients with MODS > 9)
Number of subjects: 450
Study 30304428 — intervention group
Group type: COMPARATOR
Intervention: Sham hemoperfusion plus standard therapy (n=148 patients with MODS > 9)
Number of subjects: 450
Study 27900995 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat follow-up (WFU)
Number of subjects: 108
Study 27900995 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up (TFU)
Number of subjects: 108
Study 24518646 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers/Promotores de Salud (CHW/PS) services
Number of subjects: 444
Study 24518646 — intervention group
Group type: COMPARATOR
Intervention: Community resources utilization
Number of subjects: 444
Study 23029625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (4-month paper-pencil and PC-based guided intervention)
Number of subjects: 0
Study 23029625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study 23029625 — intervention group
Group type: COMPARATOR
Intervention: Social control
Number of subjects: 0
Study 23029625 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study 21037440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Surgery (ES)
Number of subjects: 180
Study 21037440 — intervention group
Group type: COMPARATOR
Intervention: Preoperative Biliary Drainage (PBD)
Number of subjects: 180
Study 21037440 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to surgery
Number of subjects: 180
Study 17413108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding counseling
Number of subjects: 98
Study 17413108 — intervention group
Group type: COMPARATOR
Intervention: Standard health care messages (Control)
Number of subjects: 98
Study 16215330 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy with specific adjuvant exercise
Number of subjects: 100
Study 16215330 — intervention group
Group type: COMPARATOR
Intervention: Sham manual therapy with specific adjuvant exercise
Number of subjects: 100
Study 11991778 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 20
Study 11991778 — intervention group
Group type: COMPARATOR
Intervention: Linear Periodization (LP)
Number of subjects: 20
Study 10754344 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma apolipoprotein B levels
Number of subjects: 42
Study 10754344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracellular magnesium levels
Number of subjects: 42
Study 10754344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 42
Study 10754344 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 42
Study 7530501 — intervention group
Group type: EXPERIMENTAL
Intervention: R760Q mutation
Number of subjects: 17
Study 7530501 — intervention group
Group type: EXPERIMENTAL
Intervention: Other arginine substitutions (R760W, R760Q, R808C, R870W)
Number of subjects: 17
Study 2191977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of autologous fibronectin with citric acid demineralisation
Number of subjects: 4
Study 2191977 — intervention group
Group type: COMPARATOR
Intervention: Citric acid demineralisation alone (Control)
Number of subjects: 4
Study 356250 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium (Voltaren)
Number of subjects: 36
Study 356250 — intervention group
Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 36
Study 30784233 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated preventive psychological intervention (IPPI) and N-acetyl-l-cysteine (NAC)
Number of subjects: 200
Study 30784233 — intervention group
Group type: COMPARATOR
Intervention: Integrated preventive psychological intervention (IPPI) and Placebo
Number of subjects: 200
Study 30784233 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-cysteine (NAC) and psychological stress management
Number of subjects: 200
Study 30784233 — intervention group
Group type: COMPARATOR
Intervention: Placebo and psychological stress management
Number of subjects: 200
Study 28259151 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 974
Study 28259151 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified emotion-focused mindfulness (sEFM)
Number of subjects: 974
Study 28259151 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 974
Study 26218683 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of fractured ribs
Number of subjects: 189
Study 26218683 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional fractured rib
Number of subjects: 189
Study 26218683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower rib fractures
Number of subjects: 189
Study 23305133 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD) group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of chlorhexidine (CHX) gel + CHX rinses for 60 days
Number of subjects: 38
Study 23305133 — intervention group
Group type: COMPARATOR
Intervention: Control group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of placebo gel + placebo rinses for 60 days
Number of subjects: 38
Study 21963017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk with micronutrients (LFM+M)
Number of subjects: 139
Study 21963017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (LFM)
Number of subjects: 139
Study 21963017 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 139
Study 19702819 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF-SnF2 mouth rinse and toothpaste, used twice daily for 8 months
Number of subjects: 194
Study 19702819 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse and toothpaste, used twice daily for 8 months
Number of subjects: 194
Study 19702819 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF-SnF2 mouth rinse and toothpaste
Number of subjects: 194
Study 19702819 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse and toothpaste
Number of subjects: 194
Study 16722802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4% adjunctive regimen with cyclosporin-A
Number of subjects: 52
Study 16722802 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin-A monotherapy
Number of subjects: 52
Study 15031393 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention aimed at increasing control and support at work
Number of subjects: 221
Study 15031393 — intervention group
Group type: COMPARATOR
Intervention: Catering staff (control group)
Number of subjects: 221
Study 11189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Indicator Dressing (SIG)
Number of subjects: 35
Study 11189544 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid Alginate Dressing (HAD)
Number of subjects: 35
Study 9325829 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial bandaging system
Number of subjects: 29
Study 9325829 — intervention group
Group type: COMPARATOR
Intervention: Charing Cross bandaging system
Number of subjects: 29
Study 8384186 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine/caffeine combination (20mg/200mg)
Number of subjects: 180
Study 8384186 — intervention group
Group type: COMPARATOR
Intervention: ephedrine (20mg)
Number of subjects: 180
Study 8384186 — intervention group
Group type: COMPARATOR
Intervention: caffeine (200mg)
Number of subjects: 180
Study 8384186 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 3770280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion managed according to routine delivery unit practice (n = 36)
Number of subjects: 164
Study 3770280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion rates halved (n = 45)
Number of subjects: 164
Study 3770280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion rates quartered (n = 43)
Number of subjects: 164
Study 3770280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion discontinued (n = 40)
Number of subjects: 164
Study 3770280 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction during labour
Number of subjects: 164
Study 3770280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatraemic infants
Number of subjects: 164
Study 30194644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alone
Number of subjects: 100
Study 30194644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad
Number of subjects: 100
Study 30194644 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 29145993 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bioabsorbable polymer spray
Number of subjects: 40
Study 29145993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40